A citation-based method for searching scientific literature


List of co-cited articles
146 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
34

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
Richard S Finn, Shukui Qin, Masafumi Ikeda, Peter R Galle, Michel Ducreux, Tae-You Kim, Masatoshi Kudo, Valeriy Breder, Philippe Merle, Ahmed O Kaseb,[...]. N Engl J Med 2020
959
34

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
Anthony B El-Khoueiry, Bruno Sangro, Thomas Yau, Todd S Crocenzi, Masatoshi Kudo, Chiun Hsu, Tae-You Kim, Su-Pin Choo, Jörg Trojan, Theodore H Welling,[...]. Lancet 2017
34

A global view of hepatocellular carcinoma: trends, risk, prevention and management.
Ju Dong Yang, Pierre Hainaut, Gregory J Gores, Amina Amadou, Amelie Plymoth, Lewis R Roberts. Nat Rev Gastroenterol Hepatol 2019
778
26

Hepatocellular carcinoma.
Alejandro Forner, María Reig, Jordi Bruix. Lancet 2018
26

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
Andrew X Zhu, Richard S Finn, Julien Edeline, Stephane Cattan, Sadahisa Ogasawara, Daniel Palmer, Chris Verslype, Vittorina Zagonel, Laetitia Fartoux, Arndt Vogel,[...]. Lancet Oncol 2018
887
23

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Masatoshi Kudo, Richard S Finn, Shukui Qin, Kwang-Hyub Han, Kenji Ikeda, Fabio Piscaglia, Ari Baron, Joong-Won Park, Guohong Han, Jacek Jassem,[...]. Lancet 2018
19

Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features.
Julien Calderaro, Benoît Rousseau, Giuliana Amaddeo, Marion Mercey, Cécile Charpy, Charlotte Costentin, Alain Luciani, Elie-Serge Zafrani, Alexis Laurent, Daniel Azoulay,[...]. Hepatology 2016
199
19

Immune-based therapies for hepatocellular carcinoma.
David J Pinato, Nadia Guerra, Petros Fessas, Ravindhi Murphy, Takashi Mineo, Francesco A Mauri, Sujit K Mukherjee, Mark Thursz, Ching Ngar Wong, Rohini Sharma,[...]. Oncogene 2020
54
19

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L Topalian, F Stephen Hodi, Julie R Brahmer, Scott N Gettinger, David C Smith, David F McDermott, John D Powderly, Richard D Carvajal, Jeffrey A Sosman, Michael B Atkins,[...]. N Engl J Med 2012
15

Sorafenib in advanced hepatocellular carcinoma.
Josep M Llovet, Sergio Ricci, Vincenzo Mazzaferro, Philip Hilgard, Edward Gane, Jean-Frédéric Blanc, Andre Cosme de Oliveira, Armando Santoro, Jean-Luc Raoul, Alejandro Forner,[...]. N Engl J Med 2008
15

The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma.
Boyang Chang, Tao Huang, Huajun Wei, Lujun Shen, Duo Zhu, Wenjun He, Qifeng Chen, Huihua Zhang, Yunjian Li, Ruopan Huang,[...]. Cancer Immunol Immunother 2019
54
15


Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.
Austin G Duffy, Susanna V Ulahannan, Oxana Makorova-Rusher, Osama Rahma, Heiner Wedemeyer, Drew Pratt, Jeremy L Davis, Marybeth S Hughes, Theo Heller, Mei ElGindi,[...]. J Hepatol 2017
320
15

Hepatocellular Carcinoma.
Augusto Villanueva. N Engl J Med 2019
15


Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.
Richard S Finn, Baek-Yeol Ryoo, Philippe Merle, Masatoshi Kudo, Mohamed Bouattour, Ho Yeong Lim, Valeriy Breder, Julien Edeline, Yee Chao, Sadahisa Ogasawara,[...]. J Clin Oncol 2020
404
15

Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma.
Ann-Lii Cheng, Chiun Hsu, Stephen L Chan, Su-Pin Choo, Masatoshi Kudo. J Hepatol 2020
80
15

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.
Roy S Herbst, Jean-Charles Soria, Marcin Kowanetz, Gregg D Fine, Omid Hamid, Michael S Gordon, Jeffery A Sosman, David F McDermott, John D Powderly, Scott N Gettinger,[...]. Nature 2014
11

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Jordi Bruix, Shukui Qin, Philippe Merle, Alessandro Granito, Yi-Hsiang Huang, György Bodoky, Marc Pracht, Osamu Yokosuka, Olivier Rosmorduc, Valeriy Breder,[...]. Lancet 2017
11

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.
Ghassan K Abou-Alfa, Tim Meyer, Ann-Lii Cheng, Anthony B El-Khoueiry, Lorenza Rimassa, Baek-Yeol Ryoo, Irfan Cicin, Philippe Merle, YenHsun Chen, Joong-Won Park,[...]. N Engl J Med 2018
791
11

Immunotherapy for hepatocellular carcinoma: Current and future.
Michael P Johnston, Salim I Khakoo. World J Gastroenterol 2019
60
11

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy.
Sandip Pravin Patel, Razelle Kurzrock. Mol Cancer Ther 2015
11

Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.
Ziyu Liu, Yan Lin, Jinyan Zhang, Yumei Zhang, Yongqiang Li, Zhihui Liu, Qian Li, Ming Luo, Rong Liang, Jiazhou Ye. J Exp Clin Cancer Res 2019
52
11

PD-1/PD-L1 inhibitors.
Joel Sunshine, Janis M Taube. Curr Opin Pharmacol 2015
302
11


Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.
Joon Hyeok Lee, Jeong-Hoon Lee, Young-Suk Lim, Jong Eun Yeon, Tae-Jin Song, Su Jong Yu, Geum-Youn Gwak, Kang Mo Kim, Yoon Jun Kim, Jae Won Lee,[...]. Gastroenterology 2015
235
11

Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib.
Shao-Lai Zhou, Zheng-Jun Zhou, Zhi-Qiang Hu, Xiao-Wu Huang, Zheng Wang, Er-Bao Chen, Jia Fan, Ya Cao, Zhi Dai, Jian Zhou. Gastroenterology 2016
272
11

Epidemiology and Management of Hepatocellular Carcinoma.
Laura Kulik, Hashem B El-Serag. Gastroenterology 2019
422
11

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Andrew X Zhu, Yoon-Koo Kang, Chia-Jui Yen, Richard S Finn, Peter R Galle, Josep M Llovet, Eric Assenat, Giovanni Brandi, Marc Pracht, Ho Yeong Lim,[...]. Lancet Oncol 2019
556
11


Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial.
Shukui Qin, Zhenggang Ren, Zhiqiang Meng, Zhendong Chen, Xiaoli Chai, Jianping Xiong, Yuxian Bai, Lin Yang, Hong Zhu, Weijia Fang,[...]. Lancet Oncol 2020
114
11

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome.
Hashem O Alsaab, Samaresh Sau, Rami Alzhrani, Katyayani Tatiparti, Ketki Bhise, Sushil K Kashaw, Arun K Iyer. Front Pharmacol 2017
618
11

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy.
Jonathan J Havel, Diego Chowell, Timothy A Chan. Nat Rev Cancer 2019
761
11


Building on the anti-PD1/PD-L1 backbone: combination immunotherapy for cancer.
Alvaro H Ingles Garces, Lewis Au, Robert Mason, Jennifer Thomas, James Larkin. Expert Opin Investig Drugs 2019
16
18


Novel drugs in clinical development for hepatocellular carcinoma.
Oliver Waidmann, Jörg Trojan. Expert Opin Investig Drugs 2015
28
11

Tumor mutational load predicts survival after immunotherapy across multiple cancer types.
Robert M Samstein, Chung-Han Lee, Alexander N Shoushtari, Matthew D Hellmann, Ronglai Shen, Yelena Y Janjigian, David A Barron, Ahmet Zehir, Emmet J Jordan, Antonio Omuro,[...]. Nat Genet 2019
11

Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept.
Stefania De Lorenzo, Francesco Tovoli, Maria Aurelia Barbera, Francesca Garuti, Andrea Palloni, Giorgio Frega, Ingrid Garajovà, Alessandro Rizzo, Franco Trevisani, Giovanni Brandi. Sci Rep 2018
21
14

Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma.
Mohamed A Abd El Aziz, Antonio Facciorusso, Tarek Nayfeh, Samer Saadi, Mohamed Elnaggar, Christian Cotsoglou, Rodolfo Sacco. Vaccines (Basel) 2020
11
27

Molecular therapies and precision medicine for hepatocellular carcinoma.
Josep M Llovet, Robert Montal, Daniela Sia, Richard S Finn. Nat Rev Clin Oncol 2018
561
11

Molecular therapies for HCC: Looking outside the box.
Sandrine Faivre, Lorenza Rimassa, Richard S Finn. J Hepatol 2020
109
11

Nivolumab for the treatment of hepatocellular carcinoma.
Fabian Finkelmeier, Oliver Waidmann, Joerg Trojan. Expert Rev Anticancer Ther 2018
40
11

The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors.
David Yin-Wei Lin, Yoshimasa Tanaka, Masashi Iwasaki, Apostolos G Gittis, Hua-Poo Su, Bunzo Mikami, Taku Okazaki, Tasuku Honjo, Nagahiro Minato, David N Garboczi. Proc Natl Acad Sci U S A 2008
223
7

Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1).
Krzysztof M Zak, Przemyslaw Grudnik, Katarzyna Guzik, Bartosz J Zieba, Bogdan Musielak, Alexander Dömling, Grzegorz Dubin, Tad A Holak. Oncotarget 2016
149
7


Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1.
Krzysztof M Zak, Radoslaw Kitel, Sara Przetocka, Przemyslaw Golik, Katarzyna Guzik, Bogdan Musielak, Alexander Dömling, Grzegorz Dubin, Tad A Holak. Structure 2015
205
7

Cancer immunotherapy using checkpoint blockade.
Antoni Ribas, Jedd D Wolchok. Science 2018
7

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms.
Richard V Parry, Jens M Chemnitz, Kenneth A Frauwirth, Anthony R Lanfranco, Inbal Braunstein, Sumire V Kobayashi, Peter S Linsley, Craig B Thompson, James L Riley. Mol Cell Biol 2005
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.